At the end of November 2022, The New England Journal of Medicine published results from a clinical trial for a new Alzheimer’s drug. This was one of the most extensive clinical trials for an Alzheimer’s drug, with many participants from groups historically underrepresented in Alzheimer’s treatment trials or with comorbidities that might impact the drug’s […]